Melanoma Clinical Trials
A Phase 1b/3 study of Talimogene Laherparepvec in combination with pembrolizumab (MK-3475) for treatment of Stage IIIB to IVM1c Melanoma that cannot be surgically removed (20110265 MASTERKEY-265).
- Patients with BRAF wild-type mutations may have had chemotherapy, immunotherapy, or targeted therapy in an adjuvant setting (additional treatment to primary treatment) for cancer that cannot be surgically removed.
- Patients may have received the following treatment ONLY in the adjuvant setting: anti-CD137, ipilimumab or other CTLA-4 inhibitor, talimogene laherparepvec, tumor vaccine, or any other oncolytic viruses or drugs specifically targeting T-cell co-stimulation or checkpoint pathways.
- Patients treated with BRAF inhibitors with, or without a MEK inhibitor as their only prior systemic treatment are eligible for this study.
- Patients may not have received treatment with pembrolizumab, or any other inhibitor of PD-1, PD-L1, and PD-L2.
Schedule a Consultation Today!
Your health is important, and we welcome the opportunity to help you heal.
To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or use our interactive Online Appointment Request Form.